Revealing new utilities of MRD Assays in Patients with Unresectable Pancreatic Cancer

Pancreatic adenocarcinoma (PC) is one of the most lethal diseases with incidence rising in Asian-Pacific populations, especially in Japan^1,2. While minimal residual disease (MRD) assessment using circulating tumor DNA (ctDNA) has been shown to be clinically relevant for assessing treatment efficacy in select cancers³, utility in PC is unclear. We conducted a prospective study (ARTEMIS-PC) to evaluate the utility of a personalized, tumor-informed MRD assay in PC